Company research
Anbio Biotechnology
CIK 1982708Updated Sep 26, 2026
SecurityNNNN · NASDAQ · equity
NNNN price & chart
Loading TradingView…
NASDAQ:NNNN on TradingView ↗About the company
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. By offering a versatile range of products, we ensure that healthcare providers and patients alike can access reliable and efficient diagnostic tools regardless of the healthcare setting.
In the news
No coverage from other publishers is available.
Seeking Alpha
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| ASSETS | |||
| AssetsUSD | 30,242,859Source | 18,921,784Source | 15,811,768Source |
| Current assets: | |||
| Cash and Cash Equivalents, at Carrying ValueUSD | 7,766,738Source | 11,760,859Source | 9,687,976Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 3,655,964Source | 1,064,794Source | 1,884,960Source |
| Assets, CurrentUSD | 30,242,859Source | 18,534,344Source | 15,749,631Source |
| Prepaid Expense and Other Assets, CurrentUSD | 607,072Source | 25,606Source | 403,868Source |
| LIABILITIES AND EQUITY | |||
| LiabilitiesUSD | 87,836Source | 1,730,234Source | 993,060Source |
| Stockholders’ equity: | |||
| Retained Earnings (Accumulated Deficit)USD | 23,577,004Source | 17,173,541Source | 14,800,699Source |
| Stockholders' Equity Attributable to ParentUSD | 30,155,023Source | 17,191,550Source | 14,818,708Source |
| Additional Paid in Capital, Common StockUSD | 6,563,630Source | 3,780Source | 3,780Source |
| Liabilities and EquityUSD | 30,242,859Source | 18,921,784Source | 15,811,768Source |
| Current liabilities: | |||
| Liabilities, CurrentUSD | 87,836Source | 1,730,234Source | 993,060Source |
| Accounts Payable, CurrentUSD | 0Source | 1,625,255Source | 827,151Source |
| Additional Financial Items | |||
| Short-term InvestmentsUSD | 4,134,493Source | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Cash flows from operating activities: | |||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Changes in operating assets and liabilities: | |||
| Increase (Decrease) in Accounts ReceivableUSD | 2,591,170Source | -820,166Source | 1,884,960Source |
| Increase (Decrease) in InventoriesUSD | — | — | -353,872Source |
| Increase (Decrease) in Accounts PayableUSD | -1,625,255Source | 798,104Source | -580,891Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -6,739,075Source | 2,080,387Source | 898,367Source |
| Cash flows from investing activities: | |||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -4,202,496Source | 337,101Source | 1,730,173Source |
| Cash flows from financing activities: | |||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,947,450Source | -344,605Source | -42,835Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 7,766,738Source | 11,760,859Source | 9,687,976Source |
| Additional Financial Items | |||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 493,562Source | 20,469Source | 119,419Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Investment Income, InterestUSD | 142,023Source | 337,511Source | 165,336Source |
| Net Income (Loss) Attributable to ParentUSD | 6,403,463Source | 2,372,842Source | 2,253,709Source |
| Nonoperating Income (Expense)USD | 635,723Source | 377,475Source | 292,780Source |
| Operating ExpensesUSD | 1,775,422Source | 3,890,017Source | 1,399,940Source |
| Proceeds from Issuance of Common StockUSD | 7,230,000Source | — | — |
| Realized Investment Gains (Losses)USD | -68,003Source | 337,101Source | 163,388Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 8,646,844Source | 8,185,146Source | 6,711,990Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Total RevenueUSD | 8,646,844Source | 8,185,146Source | 6,711,990Source |
| Cost of Goods and Services Sold | — | — | — |
| Selling, General and Administrative ExpenseUSD | 1,574,117Source | 3,435,790Source | 1,265,240Source |
| Operating Income (Loss)USD | 5,767,740Source | 1,995,367Source | 1,960,929Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 6,403,463Source | 2,372,842Source | 2,253,709Source |
| Income Tax Expense (Benefit)USD | 0Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | 6,403,463Source | 2,372,842Source | 2,253,709Source |
| Earnings Per Share, BasicUSD per share | 0.15Source | 0.06Source | 0.11Source |
| Earnings Per Share, DilutedUSD per share | 0.15Source | 0.06Source | 0.11Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 43,672,022Source | 42,291,202Source | 21,435,316Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 43,672,022Source | — | — |
| Additional Financial Items | |||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 493,562Source | 20,469Source | 119,419Source |
| Gross ProfitUSD | 7,543,162Source | 5,885,384Source | 3,360,869Source |
| Interest Income, OtherUSD | — | 337,101Source | 163,388Source |
| Investment Income, InterestUSD | 142,023Source | 337,511Source | 165,336Source |
| Nonoperating Income (Expense)USD | 635,723Source | 377,475Source | 292,780Source |
| Operating ExpensesUSD | 1,775,422Source | 3,890,017Source | 1,399,940Source |
| Realized Investment Gains (Losses)USD | -68,003Source | 337,101Source | 163,388Source |
| Research and Development ExpenseUSD | 201,305Source | 454,227Source | 134,700Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 8,646,844Source | 8,185,146Source | 6,711,990Source |
Offerings
Registration 333-284106
- Gross proceeds
- 8000000.0
- Net proceeds
- 7440000.0
- Deal price
- 5.0
- Shares
- 1600000
- Offering price
- $5.00
- Ticker
- NNNN